Intersect ENT (XENT) stock price, revenue, and financials

Intersect ENT market cap is $901.4 m, and annual revenue was $80.55 m in FY 2020

$901.4 M

XENT Mkt cap, 14-Sept-2021

$27.3 M

Intersect ENT Revenue Q2, 2021
Intersect ENT Gross profit (Q2, 2021)19 M
Intersect ENT Gross profit margin (Q2, 2021), %69.5%
Intersect ENT Net income (Q2, 2021)-16.6 M
Intersect ENT EBIT (Q2, 2021)-16.1 M
Intersect ENT Cash, 31-Mar-202114.4 M
Intersect ENT EV905.2 M
Get notified regarding key financial metrics and revenue changes at Intersect ENTLearn more
Banner background

Intersect ENT Revenue

Intersect ENT revenue was $80.55 m in FY, 2020 which is a 26.2% year over year decrease from the previous period.

Embed Graph

Intersect ENT Revenue Breakdown

Embed Graph

Intersect ENT revenue breakdown by business segment: 92.3% from PROPEL family of products, 6.6% from SINUVA and 1.1% from Other

Intersect ENT Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

108.5m109.1m80.6m

Revenue growth, %

13%1%(26%)

Cost of goods sold

22.6m21.8m30.3m

Gross profit

85.9m87.4m50.2m

Gross profit Margin, %

79%80%62%

R&D expense

19.3m24.3m19.4m

General and administrative expense

91.6m108.5m98.6m

Operating expense total

110.9m132.8m117.9m

EBIT

(25.0m)(45.4m)(67.7m)

EBIT margin, %

(23%)(42%)(84%)

Interest expense

2.8m

Pre tax profit

(72.7m)

Income tax expense

(416.0k)

Net Income

(22.9m)(43.0m)(72.3m)

EPS

(0.8)(1.4)(2.2)

Intersect ENT Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

13.4m34.8m9.9m19.8m9.5m20.7m13.5m

Accounts Receivable

8.3m11.5m14.4m16.6m19.6m19.1m14.6m

Prepaid Expenses

2.9m2.7m2.3m3.5m

Inventories

951.0k1.5m1.3m8.5m11.6m17.0m12.1m

Current Assets

60.3m141.2m125.3m130.3m134.7m129.1m118.2m

PP&E

1.5m3.2m4.1m4.8m5.9m6.3m5.6m

Goodwill

46.6m

Total Assets

63.0m144.6m129.8m135.6m141.0m147.9m227.4m

Accounts Payable

2.1m1.9m3.3m3.4m6.2m4.1m6.0m

Current Liabilities

8.1m13.1m14.4m17.7m19.7m18.9m44.2m

Long-term debt

10.9m17.7m

Total Debt

10.9m17.7m

Total Liabilities

15.4m18.4m20.0m29.8m160.4m

Common Stock

30.0k31.0k32.0k33.0k

Preferred Stock

Additional Paid-in Capital

150.4m253.5m262.9m282.1m308.8m348.7m370.1m

Retained Earnings

(96.6m)(123.3m)(148.5m)(164.8m)(187.8m)(230.8m)(303.1m)

Total Equity

53.8m130.2m114.4m117.2m121.0m118.1m67.0m

Financial Leverage

1.2 x1.1 x1.1 x1.2 x1.2 x1.3 x3.4 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

2.7m19.2m14.2m30.3m19.3m38.0m14.4m16.4m10.6m14.0m18.6m10.5m11.8m10.2m8.6m9.4m10.4m34.2m29.5m56.9m14.4m

Accounts Receivable

4.5m4.9m8.0m8.8m8.5m9.5m10.0m10.0m12.3m12.3m11.7m14.3m14.6m14.4m17.3m15.5m13.2m10.3m7.7m11.9m14.6m

Prepaid Expenses

552.0k1.2m1.3m1.3m1.7m1.8m1.2m1.4m1.4m1.4m1.6m2.1m1.9m2.5m2.4m2.0m3.8m2.5m2.0m2.9m4.0m

Inventories

2.8m2.7m2.8m3.2m3.7m4.9m5.9m7.2m7.1m8.0m8.7m8.5m9.1m11.1m13.9m15.7m16.9m17.0m14.0m11.2m13.2m

Current Assets

10.6m62.4m55.0m149.8m145.0m133.2m128.9m127.2m119.2m121.7m124.5m128.1m130.6m132.0m131.2m126.7m123.2m117.6m159.5m156.7m102.3m

PP&E

1.7m1.6m1.8m3.2m3.1m3.4m3.8m3.9m4.2m4.2m4.6m4.9m4.7m5.1m6.0m6.1m6.1m6.2m5.9m5.6m5.2m

Goodwill

46.6m

Total Assets

14.5m64.1m57.9m153.2m148.3m136.8m133.0m131.4m123.7m126.3m129.5m133.2m135.6m137.7m139.0m134.1m130.3m135.9m176.8m173.1m210.4m

Accounts Payable

2.7m2.1m2.0m2.5m3.2m2.9m2.6m3.2m2.3m2.5m2.5m2.9m3.0m4.0m4.2m3.8m4.8m4.9m2.6m4.6m6.9m

Short-term debt

715.0k35.0k2.2m

Current Liabilities

8.0m7.2m7.1m10.2m13.4m11.3m10.7m13.6m12.6m12.4m14.7m14.3m12.7m17.5m20.1m16.0m19.4m17.7m14.1m19.8m43.5m

Long-term debt

1.0m30.0k10.3m73.5m9.0m15.9m

Total Debt

1.7m65.0k10.3m73.5m9.0m18.2m

Total Liabilities

8.4m7.2m8.2m11.5m14.8m12.6m11.9m14.7m13.5m13.2m15.5m14.8m13.2m17.9m20.3m16.0m19.4m28.0m87.7m91.8m158.2m

Common Stock

2.0k23.0k24.0k28.0k28.0k28.0k28.0k29.0k29.0k29.0k29.0k30.0k30.0k30.0k31.0k31.0k32.0k33.0k33.0k33.0k33.0k

Preferred Stock

Additional Paid-in Capital

2.3m149.8m151.6m249.5m251.1m255.5m258.3m260.3m265.3m270.5m275.7m289.5m297.6m302.6m317.2m327.9m333.6m356.1m360.4m364.2m375.3m

Retained Earnings

(87.0m)(92.9m)(102.0m)(107.8m)(117.5m)(131.5m)(137.4m)(143.7m)(155.2m)(157.4m)(161.7m)(171.0m)(175.1m)(182.7m)(198.6m)(210.0m)(222.8m)(248.3m)(271.4m)(282.9m)(323.1m)

Total Equity

(84.7m)56.9m49.7m141.7m133.6m124.2m121.1m116.7m110.2m113.1m114.0m118.4m122.4m119.8m118.7m118.1m110.9m107.9m89.1m81.4m52.3m

Financial Leverage

-0.2 x1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.1 x1.2 x1.3 x2 x2.1 x4 x

Intersect ENT Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.4m)(26.6m)(25.2m)(16.4m)(22.9m)(43.0m)(72.3m)

Depreciation and Amortization

1.2m1.5m1.9m2.7m2.8m

Accounts Receivable

(4.1m)(3.1m)(3.0m)(2.2m)(3.0m)503.0k5.0m

Inventories

(541.0k)(544.0k)(1.7m)(2.9m)(2.5m)(5.1m)6.6m

Accounts Payable

645.0k(230.0k)1.2m203.0k2.1m(1.2m)1.5m

Cash From Operating Activities

1.1m21.4m(20.1m)(8.0m)(13.8m)(27.3m)(35.7m)

Purchases of PP&E

(367.0k)(1.5m)(2.1m)(2.3m)(2.1m)(3.7m)(873.0k)

Cash From Investing Activities

(35.5m)(56.7m)(6.9m)9.2m(10.0m)18.9m(22.7m)

Cash From Financing Activities

54.6m98.2m2.0m8.8m13.5m19.5m68.7m

Net Change in Cash

10.0m(10.4m)11.2m10.4m

Interest Paid

53.0k1.0m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(8.8m)(14.7m)(5.3m)(11.2m)(20.9m)(8.2m)(14.2m)(20.4m)(6.7m)(8.9m)(13.2m)(6.1m)(10.3m)(17.9m)(10.8m)(22.2m)(35.0m)(17.5m)(40.7m)(52.1m)(20.0m)

Depreciation and Amortization

281.0k434.0k140.0k303.0k541.0k261.0k540.0k832.0k328.0k689.0k1.1m414.0k837.0k1.3m588.0k1.3m2.0m496.0k991.0k1.5m1.2m

Accounts Receivable

(313.0k)(734.0k)339.0k(488.0k)(119.0k)2.0m1.5m1.5m2.1m2.2m2.7m2.3m1.9m2.2m2.3m4.1m6.4m8.8m11.5m7.2m(172.0k)

Inventories

(571.0k)(483.0k)(279.0k)(652.0k)(1.2m)(984.0k)(1.9m)(3.2m)(1.5m)(2.4m)(3.1m)(24.0k)(659.0k)(2.6m)(2.2m)(3.8m)(5.0m)(151.0k)2.8m5.6m(1.1m)

Accounts Payable

(103.0k)592.0k(255.0k)300.0k1.1m989.0k525.0k1.4m(863.0k)(645.0k)(662.0k)(406.0k)(470.0k)230.0k(1.3m)(1.8m)(771.0k)634.0k(1.5m)555.0k1.1m

Cash From Operating Activities

(9.1m)(13.0m)(5.6m)(7.9m)(12.9m)(7.0m)(12.5m)(15.1m)(5.3m)(5.8m)(5.3m)(3.6m)(6.5m)(8.4m)(6.9m)(15.9m)(20.0m)(6.0m)(20.2m)(25.1m)(16.8m)

Purchases of PP&E

(246.0k)(291.0k)(295.0k)(910.0k)(1.2m)(508.0k)(1.0m)(1.6m)(454.0k)(981.0k)(1.7m)(344.0k)(549.0k)(1.2m)(1.2m)(1.8m)(2.6m)(137.0k)(533.0k)(722.0k)(467.0k)

Cash From Investing Activities

(246.0k)(34.7m)6.0m(72.3m)(78.4m)9.9m(9.0m)(4.4m)5.9m7.1m8.4m(10.6m)(10.9m)(12.0m)1.6m6.3m11.0m16.4m(36.8m)(4.7m)17.6m

Long-term Borrowings

(343.0k)(1.4m)

Cash From Financing Activities

(249.0k)54.6m424.0k97.1m97.2m200.0k1.1m1.2m136.0k2.9m5.6m4.9m9.4m10.7m4.5m9.4m9.8m3.1m65.8m65.9m1.1m

Net Change in Cash

(9.5m)6.9m821.0k16.9m5.9m3.2m(20.4m)(18.4m)780.0k4.2m8.7m(9.3m)(8.0m)(9.7m)(871.0k)(106.0k)890.0k13.5m8.8m36.2m1.8m

Intersect ENT Ratios

USDQ2, 2014

Financial Leverage

-0.2 x

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Accounts

2.4 k

Facilities

1

Patents (US)

30

Patents Issued

77

Patents Pending

37

Patients

150 k

Products

2

Trademarks

29

Trademarks (US)

4

Trademarks Pending

35

Intersect ENT Human Capital

Job Roles

FY, 2020FY, 2019FY, 2018
Research and Development22.9%19.2%20.4%
Sales and Administration58.9%62.7%57.8%
Manufacturing18.2%18.2%21.9%

Intersect ENT Employee Rating

2.334 votes
Culture & Values
2.4
Work/Life Balance
2.8
Senior Management
2.4
Salary & Benefits
3
Career Opportunities
2.7
Source